Journal
NATURE REVIEWS CANCER
Volume 13, Issue 9, Pages 637-651Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3546
Keywords
-
Categories
Funding
- Associazione Italiana Ricerca sul Cancro
Ask authors/readers for more resources
Activation of autocrine and paracrine signalling by endothelin 1 (ET1) binding to its receptors elicits pleiotropic effects on tumour cells and on the host microenvironment. This activation modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal transition, chemoresistance and neovascularization, thus providing a strong rationale for targeting ET1 receptors in cancer. In this Review, we discuss the advances in our understanding of the diverse biological roles of ET1 in cancer and describe the latest preclinical and clinical progress that has been made using small-molecule antagonists of ET1 receptors that inhibit ET1-driven signalling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available